Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIDaC
2025-520792-67-00Phase 3Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Time to disease progression or death. Planned start Sep 2025; status: authorised.
02
Drugs
pembrolizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-520792-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520792-67-00.